Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06
  • 3-Aminobenzamide (PARP-IN-1): Potent PARP Inhibitor for P...

    2026-01-15

    3-Aminobenzamide (PARP-IN-1): Potent PARP Inhibitor for Poly (ADP-ribose) Polymerase Research

    Executive Summary: 3-Aminobenzamide (PARP-IN-1) is a potent and selective inhibitor of poly (ADP-ribose) polymerase (PARP) with an IC50 of ~50 nM in CHO cells, achieving >95% PARP inhibition at concentrations ≥1 μM without significant cytotoxicity (Grunewald et al., 2019). It mediates protection against oxidant-induced myocyte dysfunction and enhances endothelial nitric oxide-mediated vasorelaxation following oxidative stress (APExBIO). In diabetic db/db mouse models, it ameliorates renal pathology by reducing albuminuria, mesangial expansion, and podocyte depletion. Its solubility profile (≥23.45 mg/mL in water, ≥48.1 mg/mL in ethanol, ≥7.35 mg/mL in DMSO, all with ultrasonication) supports diverse experimental applications. This review benchmarks 3-Aminobenzamide's key properties, evidence, and workflow integration for advanced research.

    Biological Rationale

    Poly (ADP-ribose) polymerases (PARPs) are a family of enzymes that catalyze ADP-ribosylation, a post-translational modification critical in DNA damage repair, cell stress response, and viral infection (Grunewald et al., 2019). Humans encode 17 PARPs, while mice encode 16. Four (PARP1, PARP2, PARP5a, PARP5b) are responsible for poly-ADP-ribosylation (PARylation), while others are mono-ADP-ribosylating or non-enzymatic. Inhibition of PARP activity is a proven strategy in the study of DNA repair pathways, oxidative stress, and immune regulation. Viruses, such as coronaviruses, encode macrodomains to counteract PARP-mediated antiviral responses (Grunewald et al., 2019).

    Mechanism of Action of 3-Aminobenzamide (PARP-IN-1)

    3-Aminobenzamide is a competitive inhibitor of the NAD+ binding site of PARP enzymes. It disrupts the transfer of ADP-ribose units from NAD+ to target proteins, impeding both mono- and poly-ADP-ribosylation. This action halts the enzymatic cascade involved in DNA repair and cellular stress responses. In CHO cell-based assays, 3-Aminobenzamide demonstrates an IC50 of approximately 50 nM for PARP inhibition, with near-complete (>95%) inhibition at concentrations above 1 μM (APExBIO). This selective inhibition does not induce significant cytotoxicity in standard cell culture models.

    Evidence & Benchmarks

    • 3-Aminobenzamide inhibits PARP activity in CHO cells with an IC50 of ~50 nM and achieves >95% inhibition at ≥1 μM, with negligible cytotoxicity (APExBIO).
    • In murine models, 3-Aminobenzamide protects against oxidant-induced myocyte dysfunction during reperfusion (APExBIO).
    • The compound significantly improves acetylcholine-induced, endothelium-dependent, nitric oxide-mediated vasorelaxation in oxidative stress models (APExBIO).
    • In db/db diabetic mouse models, 3-Aminobenzamide reduces albuminuria, mesangial expansion, and podocyte depletion, indicating efficacy in diabetic nephropathy research (APExBIO).
    • Pan-PARP inhibition, including with 3-Aminobenzamide, increases replication of macrodomain-deficient coronaviruses by suppressing interferon production in primary macrophages (Grunewald et al., 2019).

    Compared to this prior review, which focuses on benchmark workflows, this article provides updated evidence on antiviral immunity and in vivo disease modeling with 3-Aminobenzamide.

    For further mechanistic insights, see this article that explores new applications in immune regulation, while the present review details direct experimental benchmarks and integration parameters.

    Applications, Limits & Misconceptions

    3-Aminobenzamide is widely used in research on DNA damage repair, oxidative stress, endothelial function, and diabetic nephropathy. It is also leveraged in virus-host interaction studies, particularly in the context of PARP-mediated antiviral immunity (Grunewald et al., 2019). The compound's low cytotoxicity and high selectivity enable its use in both in vitro and in vivo settings. However, the scope of its effectiveness is confined to models where PARP activity is a causal driver of pathology or response.

    Common Pitfalls or Misconceptions

    • 3-Aminobenzamide is not effective in models where ADP-ribosylation is mediated by non-PARP enzymes (e.g., ARTCs or sirtuins).
    • It does not reverse existing protein ADP-ribosylation; it inhibits new PARylation events.
    • Not all PARP family members are equally sensitive to 3-Aminobenzamide; selectivity is higher for PARP1 and PARP2.
    • It is not approved for diagnostic, therapeutic, or medical use; research-only applications are permitted (APExBIO).
    • Solubility and stability are highly dependent on solvent and storage temperature; improper handling degrades activity.

    Workflow Integration & Parameters

    3-Aminobenzamide (CAS: 3544-24-9, MW: 136.15, C7H8N2O) is supplied as a solid by APExBIO (SKU: A4161). For in vitro assays, dissolve at ≥23.45 mg/mL in water or ≥48.1 mg/mL in ethanol using ultrasonication. DMSO solubility is ≥7.35 mg/mL. Stock solutions should be prepared fresh or stored at -20°C for short durations; long-term solution storage is discouraged. For PARP inhibition in CHO cells, an effective working range is 50 nM–1 μM. In animal studies, dosing regimens should be titrated to achieve plasma levels corresponding to the desired inhibition window, with reference to published pharmacokinetic data where available. All shipments are on Blue Ice for stability. Only for scientific research; not for clinical use.

    This article expands on the translational framework detailed in this reference by specifying concrete solubility and handling parameters for reproducibility.

    Conclusion & Outlook

    3-Aminobenzamide (PARP-IN-1) is a validated, potent inhibitor of poly (ADP-ribose) polymerase, enabling precise modulation of DNA repair, oxidative stress, and immune pathways in both cellular and animal models. Its robust inhibition profile, low cytotoxicity, and excellent solubility make it a preferred reagent for PARP activity inhibition assays and diabetic nephropathy research. Ongoing advances in PARP biology and virus-host interactions underscore the value of 3-Aminobenzamide as a tool for dissecting ADP-ribosylation mechanisms. For ordering and full specifications, see the APExBIO product page.